LV10043B - Stable preparation on the basis of yphosphamide and method for producung thereof - Google Patents

Stable preparation on the basis of yphosphamide and method for producung thereof Download PDF

Info

Publication number: LV10043B
Authority: LV; Latvia
Prior art keywords: und; gewichts; weight; die; ifosfamid
Prior art date: 1990-08-03

Application number

LVP-92-172A

Other languages

English (en)

Latvian (lv)

Other versions

LV10043A (lv

Inventor

Sauerbier Dieter

Engel Juergen

Milsmann Echard

Molge Klaus

Isaac Otto

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-03

Filing date

1992-10-27

Publication date

1995-06-20

1992-10-27 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1994-05-10 Publication of LV10043A publication Critical patent/LV10043A/xx

1995-06-20 Publication of LV10043B publication Critical patent/LV10043B/lv

Links

HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 39
229960001101 ifosfamide Drugs 0.000 claims description 38
239000002775 capsule Substances 0.000 claims description 15
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
239000008108 microcrystalline cellulose Substances 0.000 claims description 12
235000010980 cellulose Nutrition 0.000 claims description 10
229920002678 cellulose Polymers 0.000 claims description 10
239000001913 cellulose Substances 0.000 claims description 10
239000002202 Polyethylene glycol Substances 0.000 claims 1
239000011230 binding agent Substances 0.000 claims 1
239000004067 bulking agent Substances 0.000 claims 1
239000001506 calcium phosphate Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims 1
239000000945 filler Substances 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
229920001223 polyethylene glycol Polymers 0.000 claims 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
229940078499 tricalcium phosphate Drugs 0.000 claims 1
229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
235000019731 tricalcium phosphate Nutrition 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000008101 lactose Substances 0.000 description 6
235000012222 talc Nutrition 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
229920003136 Eudragit® L polymer Polymers 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
-1 Sorbit Chemical compound 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
229910002012 Aerosil® Inorganic materials 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000406668 Loxodonta cyclotis Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
101100262128 Mus musculus Tssk6 gene Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
BMQVRJOWNGSIEG-UHFFFAOYSA-L calcium;icosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCC([O-])=O BMQVRJOWNGSIEG-UHFFFAOYSA-L 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical class [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000000523 sample Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
IPCXNCATNBAPKW-UHFFFAOYSA-N zinc;hydrate Chemical compound O.[Zn] IPCXNCATNBAPKW-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-92-172A 1990-08-03 1992-10-27 Stable preparation on the basis of yphosphamide and method for producung thereof LV10043B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4024683		1990-08-03
SG181694A SG181694G (en)	1990-08-03	1994-12-30	Solid oral administration forms containing ifosfamide as active agent

Publications (2)

Publication Number	Publication Date
LV10043A LV10043A (lv)	1994-05-10
LV10043B true LV10043B (en)	1995-06-20

Family

ID=25895607

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-92-172A LV10043B (en)	1990-08-03	1992-10-27	Stable preparation on the basis of yphosphamide and method for producung thereof

Country Status (33)

Country	Link
US (1)	US5158776A (fr)
EP (1)	EP0469440B1 (fr)
JP (2)	JP3061898B2 (fr)
KR (1)	KR0177170B1 (fr)
CN (1)	CN1046851C (fr)
AR (1)	AR247484A1 (fr)
AT (1)	ATE110261T1 (fr)
AU (2)	AU643309B2 (fr)
BG (1)	BG60900B1 (fr)
CA (1)	CA2048367C (fr)
CZ (1)	CZ280475B6 (fr)
DE (2)	DE4124481A1 (fr)
DK (1)	DK0469440T3 (fr)
EG (1)	EG19690A (fr)
ES (1)	ES2058999T3 (fr)
FI (1)	FI97951C (fr)
HK (1)	HK15695A (fr)
HR (1)	HRP920575B1 (fr)
HU (1)	HU206268B (fr)
IE (1)	IE66378B1 (fr)
IL (1)	IL99031A (fr)
LT (1)	LT3528B (fr)
LV (1)	LV10043B (fr)
MC (1)	MC2274A1 (fr)
MX (1)	MX9100441A (fr)
NO (1)	NO178252C (fr)
NZ (1)	NZ239222A (fr)
PT (1)	PT98532B (fr)
RO (1)	RO113611B1 (fr)
SG (1)	SG181694G (fr)
SI (1)	SI9111342B (fr)
SK (2)	SK279740B6 (fr)
ZA (1)	ZA916124B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0804174A4 (fr) *	1993-07-21	1998-09-09	Univ Kentucky Res Found	Gelule a plusieurs compartiments assurant une liberation controlee
ITFI970184A1 (it) *	1997-07-30	1999-01-30	Menarini Farma Ind	Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
DE19733305A1 (de) *	1997-08-01	1999-02-04	Asta Medica Ag	Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin
US6103297A (en) *	1998-01-14	2000-08-15	Matsushita Electronics Corporation	Method of manufacturing cathode-ray tube
DE19826517B4 (de) *	1998-06-15	2006-03-23	Baxter Healthcare S.A.	Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US20040253307A1 (en) *	2003-02-04	2004-12-16	Brian Hague	Sugar-free oral transmucosal solid dosage forms and uses thereof
DE102005008797A1 (de) *	2005-02-25	2006-09-07	Baxter International Inc., Deerfield	Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung
CN106413706A (zh)	2014-01-06	2017-02-15	铁治疗控股公司	三麦芽酚铁的剂量方案
GB201418710D0 (en)	2014-10-21	2014-12-03	Iron Therapeutics Holdings Ag	Dosage regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3987204A (en)	1972-09-15	1976-10-19	Sucrest Corporation	Direct compression vehicle
JPS5646807A (en) *	1979-09-27	1981-04-28	Japan Atom Energy Res Inst	Production of composition of complex gradually releasing physiologically active substance
DE3111428A1 (de) *	1981-03-24	1982-10-07	Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld	Oxazaphosphorin-4-thio-alkansulfonsaeuren und deren neutrale salze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US4618692A (en) *	1981-09-03	1986-10-21	Asta-Werke Aktiengesellschaft	4-carbamoyloxy-oxazaphosphorins
US5019385A (en) *	1984-11-09	1991-05-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Novel lymphopine LK 2 and pharmaceutic compositions containing same
ATE66609T1 (de) *	1986-07-11	1991-09-15	Asta Pharma Ag	Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
DE3804686A1 (de) *	1988-02-15	1989-08-24	Henkel Kgaa	Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten

1991
- 1991-07-15 RO RO148008A patent/RO113611B1/ro unknown
- 1991-07-24 DE DE4124481A patent/DE4124481A1/de not_active Withdrawn
- 1991-07-24 EP EP91112368A patent/EP0469440B1/fr not_active Expired - Lifetime
- 1991-07-24 MC MC912206A patent/MC2274A1/fr unknown
- 1991-07-24 US US07/733,756 patent/US5158776A/en not_active Expired - Lifetime
- 1991-07-24 ES ES91112368T patent/ES2058999T3/es not_active Expired - Lifetime
- 1991-07-24 DK DK91112368.5T patent/DK0469440T3/da active
- 1991-07-24 DE DE59102620T patent/DE59102620D1/de not_active Expired - Fee Related
- 1991-07-24 AT AT91112368T patent/ATE110261T1/de not_active IP Right Cessation
- 1991-07-30 MX MX9100441A patent/MX9100441A/es unknown
- 1991-07-31 JP JP3191414A patent/JP3061898B2/ja not_active Expired - Fee Related
- 1991-08-01 PT PT98532A patent/PT98532B/pt not_active IP Right Cessation
- 1991-08-01 EG EG46991A patent/EG19690A/xx active
- 1991-08-01 NZ NZ239222A patent/NZ239222A/xx not_active IP Right Cessation
- 1991-08-01 IL IL9903191A patent/IL99031A/en not_active IP Right Cessation
- 1991-08-01 SI SI9111342A patent/SI9111342B/sl not_active IP Right Cessation
- 1991-08-01 BG BG94934A patent/BG60900B1/bg unknown
- 1991-08-02 HU HU912594A patent/HU206268B/hu not_active IP Right Cessation
- 1991-08-02 AR AR91320329A patent/AR247484A1/es active
- 1991-08-02 NO NO913019A patent/NO178252C/no not_active IP Right Cessation
- 1991-08-02 CZ CS912409A patent/CZ280475B6/cs not_active IP Right Cessation
- 1991-08-02 SK SK2409-91A patent/SK279740B6/sk not_active IP Right Cessation
- 1991-08-02 KR KR1019910013365A patent/KR0177170B1/ko not_active Expired - Fee Related
- 1991-08-02 ZA ZA916124A patent/ZA916124B/xx unknown
- 1991-08-02 CA CA002048367A patent/CA2048367C/fr not_active Expired - Lifetime
- 1991-08-02 FI FI913710A patent/FI97951C/fi active
- 1991-08-02 IE IE277491A patent/IE66378B1/en not_active IP Right Cessation
- 1991-08-02 AU AU81589/91A patent/AU643309B2/en not_active Ceased
- 1991-08-02 CN CN91105271A patent/CN1046851C/zh not_active Expired - Fee Related
1992
- 1992-09-29 HR HRP-1342/91A patent/HRP920575B1/xx not_active IP Right Cessation
- 1992-10-27 LV LVP-92-172A patent/LV10043B/lv unknown
1993
- 1993-08-23 AU AU44836/93A patent/AU649184B2/en not_active Ceased
- 1993-09-03 LT LTIP921A patent/LT3528B/lt not_active IP Right Cessation
1994
- 1994-12-30 SG SG181694A patent/SG181694G/en unknown
1995
- 1995-02-06 HK HK15695A patent/HK15695A/xx not_active IP Right Cessation
1998
- 1998-04-27 SK SK543-98A patent/SK279739B6/sk not_active IP Right Cessation
2000
- 2000-01-14 JP JP2000006836A patent/JP3545300B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BG60900B1 (bg)	1996-06-28
US5158776A (en)	1992-10-27
HK15695A (en)	1995-02-10
HRP920575A2 (en)	1995-04-30
RO113611B1 (ro)	1998-09-30
NO178252C (no)	1996-02-21
EP0469440A1 (fr)	1992-02-05
ZA916124B (en)	1992-04-29
EP0469440B1 (fr)	1994-08-24
PT98532A (pt)	1992-06-30
SK279739B6 (sk)	1999-03-12
IL99031A (en)	1996-09-04
KR920003963A (ko)	1992-03-27
BG94934A (bg)	1993-12-24
PT98532B (pt)	1999-01-29
CA2048367C (fr)	2000-05-23
NO913019L (no)	1992-02-04
AR247484A1 (es)	1995-01-31
JPH04243828A (ja)	1992-08-31
AU4483693A (en)	1993-11-11
AU643309B2 (en)	1993-11-11
FI913710L (fi)	1992-02-04
DK0469440T3 (da)	1994-11-14
CS240991A3 (en)	1992-03-18
LV10043A (lv)	1994-05-10
JP2000229860A (ja)	2000-08-22
DE4124481A1 (de)	1992-02-06
CN1058715A (zh)	1992-02-19
SI9111342B (sl)	1998-10-31
ATE110261T1 (de)	1994-09-15
LT3528B (en)	1995-11-27
MX9100441A (es)	1992-04-01
AU649184B2 (en)	1994-05-12
CN1046851C (zh)	1999-12-01
JP3061898B2 (ja)	2000-07-10
HRP920575B1 (en)	1999-04-30
NO913019D0 (no)	1991-08-02
FI97951C (fi)	1997-03-25
MC2274A1 (fr)	1993-06-23
IL99031A0 (en)	1992-07-15
ES2058999T3 (es)	1994-11-01
KR0177170B1 (ko)	1999-03-20
EG19690A (en)	1995-09-30
NZ239222A (en)	1993-01-27
AU8158991A (en)	1992-02-06
HUT59316A (en)	1992-05-28
JP3545300B2 (ja)	2004-07-21
SG181694G (en)	1995-05-12
FI913710A0 (fi)	1991-08-02
IE912774A1 (en)	1992-02-12
CA2048367A1 (fr)	1992-02-04
CZ280475B6 (cs)	1996-01-17
HU206268B (en)	1992-10-28
IE66378B1 (en)	1995-12-27
DE59102620D1 (de)	1994-09-29
SK279740B6 (sk)	1999-03-12
NO178252B (no)	1995-11-13
FI97951B (fi)	1996-12-13
HU912594D0 (en)	1992-01-28
LTIP921A (en)	1995-03-27
SI9111342A (sl)	1998-04-30

Publication	Publication Date	Title
DE69000881T2 (de)	1993-08-12	2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
DE4215677B4 (de)	2008-01-17	Pharmazeutisches Mittel
DE69117922T2 (de)	1996-09-05	Zusammensetzungen gegen malaria
DE60035631T2 (de)	2008-05-21	Inhibitoren der Interleukin-4 Produktion
DE1792410B2 (de)	1980-03-13	Arzneimittelzubereitung zur intravenösen Injektion
DE112020001849T5 (de)	2021-12-23	Segmentierte hautpflegezusammensetzung für lipidgesundheit zum schutz der hautbarriere bei kleinkindern
DE69027220T2 (de)	1997-01-02	Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE2414868A1 (de)	1974-10-10	Arzneimittel und verfahren zu seiner herstellung
DE69414904T2 (de)	1999-05-12	Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen
DE4010079A1 (de)	1991-10-02	Pharmazeutische formulierung zur behandlung des alkoholismus
DE202013104575U1 (de)	2014-01-16	Mischung aus mikrogekapselten Aminosäuren
EP3843697B1 (fr)	2025-07-09	Préparation nettoyante douce ii
DE69128760T2 (de)	1998-04-30	Antidiarrhoeika
LV10043B (en)	1995-06-20	Stable preparation on the basis of yphosphamide and method for producung thereof
DE69839040T2 (de)	2008-05-21	Brunnenkresseextrakt enthaltende zubereitung zur äusserlichen anwendung
DE2459391C3 (de)	1978-10-19	Medizinische feste Augeneinlage
WO1996019212A1 (fr)	1996-06-27	Utilisation d'acide boswellique pour le traitement des tumeurs du cerveau
DE19940011B4 (de)	2009-04-02	Alginataufbereitung und deren Verwendung
DE10394354T5 (de)	2007-01-11	Pfanzliche Formulierung, die Centella Asiatica und Sesamum Indicum enthält, als Gehirn-Tonikum
DE3316597C1 (de)	1984-04-12	Gelförmige Zubereitung und ihre Verwendung als Pflegemittel
DE19906974C2 (de)	2003-10-09	Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
EP3843698A1 (fr)	2021-07-07	Préparation nettoyante douce
DD220782A5 (de)	1985-04-10	Verfahren zur herstellung neuartiger galenischer sulpirid-formen
DE10393805T5 (de)	2005-10-20	Pharmazeutische Formulierungen, die ß-2-Adrenorezeptor-Agonisten und Xantine enthalten
DE60310125T2 (de)	2007-10-25	Feste mucoadhesive zusammensetzung